Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01202578 · ClinicalTrials.gov registry record · Phase 2

Evaluation of the Tympanostomy Tube Delivery System

A Phase 2 study of Acute Otitis Media and Otitis Media With Effusion, sponsored by Integra LifeSciences Corporation.

Completed
Registry status
Phase 2
Development phase
53
Enrollment target
4
Study locations

NCT01202578 is a Phase 2 study of Acute Otitis Media and Otitis Media With Effusion that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 53 participants, below the 401-participant average among 8 other Acute Otitis Media trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01202578, a Phase 2 study of Acute Otitis Media and Otitis Media With Effusion, has completed, sponsored by Integra LifeSciences Corporation.

COMPLETED
Registry status
Phase 2
Development phase
53 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to evaluate the performance and safety of the Tympanostomy Tube Delivery System (TTDS) for chronic otitis media or recurrent acute otitis media.

Interventions

  • DEVICE tympanostomy tube

Study Locations (4)

Florida

  • South Coast ENT - Port Saint Lucie

Kentucky

  • Advanced ENT and Allergy - Louisville

Texas

  • Ear Medical Group - San Antonio

Washington

  • Evergreen Sinus Center - Kirkland

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2010-09
Est. Completion 2010-12
Phase Phase 2

Sponsor

Integra LifeSciences Corporation

60 total trials

What the Registry Record Tells You About NCT01202578

The ClinicalTrials.gov registry entry for NCT01202578 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 401-participant average among 8 other Acute Otitis Media trials with a reported enrollment target (87% lower). The listed sponsor is Integra LifeSciences Corporation, which has 60 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Acute Otitis Media appearing as the primary indexed condition, and to 1 intervention - of which tympanostomy tube is the first listed.

NCT01202578 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Kentucky, Texas.

Frequently Asked Questions

What is clinical trial NCT01202578 about?

NCT01202578 is a clinical study titled "Evaluation of the Tympanostomy Tube Delivery System". The purpose of this study is to evaluate the performance and safety of the Tympanostomy Tube Delivery System (TTDS) for chronic otitis media or recurrent acute otitis media.

What is the current status of trial NCT01202578?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2010-09. Estimated completion is 2010-12.

What conditions does trial NCT01202578 study?

This clinical trial studies the following conditions: Acute Otitis Media, Otitis Media With Effusion.

What interventions are being tested in trial NCT01202578?

The interventions under investigation include: tympanostomy tube (DEVICE).

Who is sponsoring clinical trial NCT01202578?

This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01202578 being conducted?

This trial has 4 study locations across Florida, Kentucky, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Otitis Media

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.